Journal
BLOOD
Volume 139, Issue 9, Pages 1264-1265Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2021014826
Keywords
-
Categories
Ask authors/readers for more resources
In this issue of Blood, Huber et al present the results of an important prospective clinical trial, showing that the combination of obinutuzumab, ibrutinib, and venetoclax produces high rates of undetectable measurable residual disease and remarkable 2-year progression-free survival in previously untreated del(17p) or TP53-mutated chronic lymphocytic leukemia (CLL) patients.
In this issue of Blood , Huber et al(1) present results of an important prospective clinical trial, demonstrating that the combination of obinutuzumab, ibrutinib, and venetoclax produces high rates of undetectable measurable residual disease and remarkable 2-year progression-free survival in previously untreated del(17p) or TP53-mutated chronic lymphocytic leukemia (CLL).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available